1: Bell RL, Lanni C, Malo PE, Brooks DW, Stewart AO, Hansen R, Rubin P, Carter GW. Preclinical and clinical activity of zileuton and A-78773. Ann N Y Acad Sci. 1993 Nov 30;696:205-15. PubMed PMID: 8109828.
2: Rao TS, Currie JL, Shaffer AF, Isakson PC. Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat. Life Sci. 1993;53(9):PL147-52. PubMed PMID: 8394967.
3: Bell RL, Brooks DW, Young PR, Lanni C, Stewart AO, Bouska J, Malo PE, Carter GW. A-78773: a selective, potent 5-lipoxygenase inhibitor. J Lipid Mediat. 1993 Mar-Apr;6(1-3):259-64. PubMed PMID: 8395248.
4: Carter GW, Bell RL, Marsh K, Lanni C, Awni WM, Bouska J, Stewart AO, Hansen R, Dubé L, Brooks DW. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. Ann N Y Acad Sci. 1994 Nov 15;744:262-73. PubMed PMID: 7825849.
5: Smith WG, Shaffer AF, Currie JL, Thompson JM, Kim S, Rao T, Isakson PC. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays. J Pharmacol Exp Ther. 1995 Dec;275(3):1332-8. PubMed PMID: 8531100.
6: Nair DG, Funk CD. A cell-based assay for screening lipoxygenase inhibitors. Prostaglandins Other Lipid Mediat. 2009 Dec;90(3-4):98-104. doi: 10.1016/j.prostaglandins.2009.09.006. Epub 2009 Oct 3. PubMed PMID: 19804839.
7: Li R, Mayer PT, Trivedi JS, Fort JJ. Polymorphism and crystallization behavior of Abbott-79175, a second-generation 5-lipoxygenase inhibitor. J Pharm Sci. 1996 Jul;85(7):773-80. PubMed PMID: 8819005.
8: Negro JM, Miralles JC, Ortiz JL, Funes E, García A. Biosynthesis inhibitors for leukotrienes in bronchial asthma. Allergol Immunopathol (Madr). 1997 Jul-Aug;25(4):209-16. Review. PubMed PMID: 9269512.
9: Bell RL, Bouska JB, Malo PE, Lanni C, Harris RR, Otis ER, Stewart AO, Brooks DW, Carter GW. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J Pharmacol Exp Ther. 1995 Feb;272(2):724-31. PubMed PMID: 7853186.
10: Anderson GD, Keys KL, De Ciechi PA, Masferrer JL. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009 Feb;58(2):109-17. doi: 10.1007/s00011-009-8149-3. PubMed PMID: 19184362.
11: McLoughlin M, Kearney AS, Palepu NR. Aqueous stability of SB 210661: kinetics and primary degradation mechanisms of an N-hydroxyurea-containing 5-lipoxygenase inhibitor. J Pharm Pharmacol. 1998 Feb;50(2):127-32. PubMed PMID: 9530978.
12: Harris RR, Wilcox D, Bell RL, Carter GW. The role of tissue mast cells in polyacrylamide gel-induced inflammation in mice. Inflamm Res. 1998 Mar;47(3):104-8. PubMed PMID: 9562335.
13: Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 1998 Aug;19(8):1393-400. PubMed PMID: 9744535.
14: Hulkower KI, Pollock JS, Walsh RE, Huang R, Otis ER, Brooks CD, Bell RL. Leukotrienes do not regulate nitric oxide production in RAW 264.7 macrophages. Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):145-9. PubMed PMID: 8931110.
15: Howarth PH, Harrison K, Lau L. The influence of 5-lipoxygenase inhibition in allergic rhinitis. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):423-4. PubMed PMID: 7613199.